Does Medicare Cover GLP-1 Medications in 2026?

Updated April 20, 2026

Yes, Medicare covers GLP-1 medications — but only for specific medical conditions, and the rules are changing fast in 2026. Historically, Medicare Part D covered GLP-1s for Type 2 diabetes and cardiovascular risk reduction, but refused to pay for them when prescribed solely for weight loss. That's the piece that's changing.

Here's the complete 2026 picture: what's covered now, what's changing in July 2026 via the new Medicare GLP-1 Bridge, and what to do in the meantime if you're a Medicare beneficiary who needs a GLP-1 today.

Currently Covered: Diabetes and Cardiovascular Risk

If you have a Medicare Part D plan, GLP-1 medications are typically covered when prescribed for:

• Type 2 diabetes (Ozempic, Mounjaro, Rybelsus, Trulicity)
• Cardiovascular risk reduction (Ozempic has an FDA indication for this; Wegovy recently added one)
• Kidney disease (Ozempic)
• Obstructive sleep apnea (Mounjaro and Zepbound have FDA approvals for this)

Copays vary dramatically by plan and tier. Common ranges:

• Preferred tier (cheapest): $30–$50/month
• Non-preferred tier: $80–$200/month
• Specialty tier: 25–33% coinsurance, sometimes $300+/month

A given GLP-1 is usually in different tiers across different plans. Ozempic and Mounjaro are typically non-preferred. Check your plan's formulary before assuming any specific price.

Historically Excluded: Weight Loss

Since Medicare's creation in 1965, Part D has been statutorily prohibited from covering drugs used solely for weight loss. That's why Wegovy and Zepbound have been out of reach for most Medicare beneficiaries even when their doctors prescribed them for obesity-related conditions. If your diagnosis was "obesity" rather than "diabetes" or "cardiovascular risk," your Part D plan rejected the claim.

The Big Change: Medicare GLP-1 Bridge (July 2026)

Launching July 1, 2026, the Medicare GLP-1 Bridge is a new program that covers Wegovy and Zepbound specifically for weight management, at a flat $50/month copay for eligible Medicare beneficiaries. This is the first major expansion of Medicare weight-loss drug coverage in program history.

The Bridge is explicitly a bridge program, intended to run until broader Part D formulary reform takes effect in January 2027. After that, expect the $50 copay to persist but be absorbed into standard Part D formularies across plans.

Key details:

• Drugs covered: Wegovy (injection and pill) and Zepbound
• Copay: $50/month
• Eligibility: Must be enrolled in Medicare Part D; some BMI thresholds apply
• Enrollment: Automatic for qualifying beneficiaries through their existing Part D plans
• Not included: Mounjaro (already covered separately under diabetes), Foundayo (too new)

CMS BALANCE Model: Full Part D Expansion January 2027

The Bridge is phase one. The CMS BALANCE Model, launching May 2026 for Medicaid and expanding to Part D in January 2027, represents a more durable restructuring:

• Full Part D coverage of Wegovy, Zepbound, and future GLP-1s for weight management
• Mandatory formulary inclusion at all Part D tiers
• Negotiated pricing through CMS direct pricing authority

If you're on Medicare and can wait until 2027, Part D coverage will be broader than anything available today. But if you need GLP-1 access now, you have two practical options.

What Medicare Beneficiaries Should Do Right Now

If your GLP-1 is for diabetes, heart, kidney, or sleep apnea

Use your Part D benefit. Verify which GLP-1 is in the lowest tier on your formulary. If you're unhappy with the tier placement, ask your doctor to file a formulary exception request — these succeed 40–80% of the time with proper documentation.

If your GLP-1 is for weight loss (before July 2026)

Part D won't cover it yet. Your best bridge option is TrumpRx, which offers:

• Wegovy injection: $199/month
• Wegovy pill: $149/month
• Zepbound: $299/month

Manufacturer savings cards do not work with Medicare, so ignore any guide recommending the $25/month Zepbound card if you're on Medicare — federal anti-kickback rules block it.

If your GLP-1 is for weight loss (after July 2026)

Wait for the Bridge program to start July 1. At $50/month for Wegovy or Zepbound, nothing else (including TrumpRx) will beat it.

Medicare vs Medicare Advantage

Medicare Advantage (Part C) plans include Part D coverage but may have their own formulary. Some Advantage plans have already announced preemptive GLP-1 coverage ahead of the federal Bridge launch. If you're in a Medicare Advantage plan, call member services directly to ask about current and upcoming GLP-1 coverage for weight management.

Patient Assistance for Medicare Beneficiaries

NovoCare's Patient Assistance Program does accept Medicare beneficiaries who meet income thresholds (roughly 400% of federal poverty level). If you qualify, Wegovy can be free even if your Part D plan denies coverage. Lilly Cares similarly covers Zepbound (but not Mounjaro) for qualifying Medicare beneficiaries.

Bottom Line Summary